Zenas BioPharma (ZBIO) Free Cash Flow (2023 - 2026)

Zenas BioPharma's Free Cash Flow history runs 4 years deep, the most recent figure standing at -$75.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 102.86% year-over-year to -$75.2 million; the TTM figure through Mar 2026 stood at -$210.5 million (down 52.8% YoY), while the FY2025 annual figure was -$172.4 million, down 43.86% from the prior year.
• Free Cash Flow was -$75.2 million for Q1 2026 at Zenas BioPharma, down from -$52.4 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$15.4 million in Q4 2023 to a low of -$75.2 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$38.3 million across 4 years, with a median of -$37.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow slumped 150.83% in 2024, then slumped 32.41% in 2025.
• A 4-year view of Free Cash Flow shows it stood at -$15.4 million in 2023, then plunged by 150.83% to -$38.6 million in 2024, then sank by 35.69% to -$52.4 million in 2025, then plunged by 43.47% to -$75.2 million in 2026.
• The last three Free Cash Flow figures came in at -$75.2 million (Q1 2026), -$52.4 million (Q4 2025), and -$41.1 million (Q3 2025), per Business Quant data.